Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Matthew J. Ahearne et al.|UCL Discovery (University College London)|2022Cited by 76
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Jennifer Santos, Jason T. Romancik, Loretta J. Nastoupil et al.|UNC Libraries|2024Cited by 0